Literature DB >> 25044306

A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States.

Alison C Kleiner1, Dennis P Cladis, Charles R Santerre.   

Abstract

BACKGROUND: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are associated with health benefits throughout life and are obtained primarily through fish and fish oil supplements. Due to the growing popularity of dietary supplements, 47 commercial fish, krill, and algal oil supplements were analyzed for EPA, DHA, and other fatty acids.
RESULTS: For fish- and krill-based supplements, the range of EPA was 81.8 to 454.6 mg g(-1) oil and DHA was 51.6 to 220.4 mg g(-1) oil. For algal oil supplements, EPA ranged from 7.7 to 151.1 mg g(-1) oil and DHA ranged from 237.8 to 423.5 mg g(-1) oil. The percentage of the stated label amount for EPA and DHA ranged from 66 to 184% and 62 to 184%, respectively. Only 10 supplements (21% of those tested) had at least 100% of the stated label amount of EPA, while 12 supplements (25% of those tested) had at least 100% of the stated amount of DHA. Over 70% of the supplements tested did not contain the stated label amount of EPA or DHA.
CONCLUSIONS: These results indicate that the quality of fish oil supplements is not being adequately monitored by manufacturers or government agencies and increased testing is needed to ensure regulatory compliance.
© 2014 Society of Chemical Industry.

Entities:  

Keywords:  DHA; EPA; dietary supplement; fatty acids; fish oil

Mesh:

Substances:

Year:  2014        PMID: 25044306     DOI: 10.1002/jsfa.6816

Source DB:  PubMed          Journal:  J Sci Food Agric        ISSN: 0022-5142            Impact factor:   3.638


  18 in total

1.  Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: potential treatment for depression.

Authors:  Poorna C R Yalagala; Dhavamani Sugasini; Sridevi Dasarathi; Kalipada Pahan; Papasani V Subbaiah
Journal:  J Lipid Res       Date:  2018-12-10       Impact factor: 5.922

2.  Are There Benefits from the Use of Fish Oil Supplements in Athletes? A Systematic Review.

Authors:  Nathan A Lewis; Diarmuid Daniels; Philip C Calder; Lindy M Castell; Charles R Pedlar
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

3.  Dietary Fat Intake and Fecundability in 2 Preconception Cohort Studies.

Authors:  Lauren A Wise; Amelia K Wesselink; Katherine L Tucker; Shilpa Saklani; Ellen M Mikkelsen; Heidi Cueto; Anders H Riis; Ellen Trolle; Craig J McKinnon; Kristen A Hahn; Kenneth J Rothman; Henrik Toft Sørensen; Elizabeth E Hatch
Journal:  Am J Epidemiol       Date:  2018-01-01       Impact factor: 4.897

4.  Application of Silver Ion High-Performance Liquid Chromatography for Quantitative Analysis of Selected n-3 and n-6 PUFA in Oil Supplements.

Authors:  Anna Czajkowska-Mysłek; Urszula Siekierko; Magdalena Gajewska
Journal:  Lipids       Date:  2016-03-03       Impact factor: 1.880

5.  Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study.

Authors:  Michael Bauer; Tasha Glenn; Jörn Conell; Natalie Rasgon; Wendy Marsh; Kemal Sagduyu; Rodrigo Munoz; Ute Lewitzka; Rita Bauer; Maximilian Pilhatsch; Scott Monteith; Peter C Whybrow
Journal:  Int J Bipolar Disord       Date:  2015-06-02

Review 6.  ω-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance.

Authors:  Hanne K Maehre; Ida-Johanne Jensen; Edel O Elvevoll; Karl-Erik Eilertsen
Journal:  Int J Mol Sci       Date:  2015-09-18       Impact factor: 5.923

Review 7.  Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).

Authors:  Eliot A Brinton; R Preston Mason
Journal:  Lipids Health Dis       Date:  2017-01-31       Impact factor: 3.876

Review 8.  Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.

Authors:  Nadeem Tajuddin; Ali Shaikh; Amir Hassan
Journal:  Diabetes Metab Syndr Obes       Date:  2016-04-19       Impact factor: 3.168

9.  Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.

Authors:  Richard S Castaldo
Journal:  Drugs Ther Perspect       Date:  2016-03-08

Review 10.  Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.

Authors:  Jonathan Fialkow
Journal:  Am J Cardiovasc Drugs       Date:  2016-08       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.